{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:21:31Z","timestamp":1770236491178,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2042,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I21HX002365"],"award-info":[{"award-number":["I21HX002365"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["K08HL122527"],"award-info":[{"award-number":["K08HL122527"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG055663-01"],"award-info":[{"award-number":["R01AG055663-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I21HX002365"],"award-info":[{"award-number":["I21HX002365"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["K08HL122527"],"award-info":[{"award-number":["K08HL122527"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG055663\u201001"],"award-info":[{"award-number":["R01AG055663\u201001"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the prescription frequency of potentially harmful prescription drugs as defined in current heart failure guidelines among elderly patients with a diagnosis of heart failure with reduced ejection fraction and their association with clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We used the Centers for Medicare &amp; Medicaid Services data from a nationally representative 5% sample for the years 2014\u20132016 to identify patients admitted to acute care hospitals with a primary diagnosis of heart failure with reduced ejection fraction. The primary exposure was filling a prescription for a potentially harmful drug. Potentially harmful drug fills were treated as a time-dependent covariate to examine their association on readmission and mortality. A total of 8993 patients met study criteria. Potentially harmful drugs were prescribed in 1077 (11.9%) patients within 90 days of discharge from the heart failure hospitalization. Non-steroidal anti-inflammatory agents were the most frequently prescribed potentially harmful drug (6.7%) followed by calcium channel blockers (4.7%), thiazolidinedione (0.59%), and select antiarrhythmic (0.33%). Factors independently associated with potentially harmful drug prescription were female gender, Hispanic ethnicity, severe obesity, among others. In the multivariable Cox model, the prescription of a potentially harmful drug was associated with an increased risk of readmission (hazard ratio 1.14; 95% confidence interval 1.05\u20131.23, P &amp;lt; 0.001). Among drug subgroups, only calcium channel blockers were associated with an increased risk of readmission (hazard ratio 1.225; 95% confidence interval 1.085\u20131.382, P = 0.0011).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In elderly patients discharged with a primary diagnosis of heart failure with reduced ejection fraction on guideline-directed medical therapy, prescription of a potentially harmful drug was frequent. Calcium channel blockers were associated with an increased risk of readmission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12752","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T02:55:27Z","timestamp":1589770527000},"page":"1862-1871","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potentially Harmful Drug Prescription in Elderly Patients with Heart Failure with Reduced Ejection Fraction"],"prefix":"10.1093","volume":"7","author":[{"given":"Paulino A.","family":"Alvarez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals & Clinics , Iowa City, IA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubo","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Sciences, University of Iowa , 200 Hawkins Drive, C44-GH, Iowa City, IA, 52242 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saket","family":"Girotra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals & Clinics , Iowa City, IA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad","family":"Mentias","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals & Clinics , Iowa City, IA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiovascular Diseases, University of Iowa Hospitals & Clinics , Iowa City, IA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary S.","family":"Vaughan Sarrazin*","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Translational Sciences, University of Iowa , 200 Hawkins Drive, C44-GH, Iowa City, IA, 52242 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,17]]},"reference":[{"key":"2026012115035710500_ehf212752-bib-0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"2026012115035710500_ehf212752-bib-0002","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMp1410241","article-title":"Paradigm shifts in heart-failure therapy\u2014a timeline","volume":"371","author":"Sacks","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0003","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","article-title":"Multimorbidity in older adults with cardiovascular disease","volume":"71","author":"Forman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0004","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","article-title":"Domain management approach to heart failure in the geriatric patient: present and future","volume":"71","author":"Gorodeski","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.amjmed.2010.08.017","article-title":"Trends in comorbidity, disability, and polypharmacy in heart failure","volume":"124","author":"Wong","year":"2011","journal-title":"Am J Med"},{"key":"2026012115035710500_ehf212752-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2026012115035710500_ehf212752-bib-0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2005.08.022","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0008","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0010","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for one year after myocardial infarction","volume":"1","author":"Julian","year":"1982","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.mayocp.2016.11.009","article-title":"Burden and timing of hospitalizations in heart failure: a community study","volume":"92","author":"Chamberlain","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2026012115035710500_ehf212752-bib-0012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"2026012115035710500_ehf212752-bib-0013","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026012115035710500_ehf212752-bib-0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamacardio.2017.4265","article-title":"Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure","volume":"3","author":"Gupta","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2296-15-130","article-title":"The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review","volume":"15","author":"Lebeau","year":"2014","journal-title":"BMC Fam Pract"},{"key":"2026012115035710500_ehf212752-bib-0016","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.amjcard.2019.01.052","article-title":"Prescription of potentially harmful drugs in young adults with heart failure and reduced ejection fraction","volume":"123","author":"Alvarez","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/clc.22917","article-title":"Sex differences in heart failure","volume":"41","author":"Eisenberg","year":"2018","journal-title":"Clin Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0018","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2008.12.037","article-title":"Heart failure in Hispanics","volume":"53","author":"Vivo","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0019","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/1753944707088184","article-title":"Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?","volume":"2","author":"Aneja","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026012115035710500_ehf212752-bib-0021","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ejheart.2004.02.005","article-title":"Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors","volume":"6","author":"Juhlin","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026012115035710500_ehf212752-bib-0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejheart.2006.05.015","article-title":"Treatments with losartan or enalapril are equally sensitive to deterioration in renal function from cyclooxygenase inhibition","volume":"9","author":"Juhlin","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026012115035710500_ehf212752-bib-0023","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.hfc.2008.03.002","article-title":"Renal consequences of prostaglandin inhibition in heart failure","volume":"4","author":"Akinbamowo","year":"2008","journal-title":"Heart Fail Clin"},{"key":"2026012115035710500_ehf212752-bib-0024","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/eurheartj\/ehv505","article-title":"Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"37","author":"Schmidt","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115035710500_ehf212752-bib-0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejheart.2008.07.013","article-title":"Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials","volume":"10","author":"Scott","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026012115035710500_ehf212752-bib-0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","article-title":"Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure","volume":"169","author":"Gislason","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026012115035710500_ehf212752-bib-0027","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/bmj.330.7504.1370","article-title":"Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study","volume":"330","author":"Hudson","year":"2005","journal-title":"BMJ"},{"key":"2026012115035710500_ehf212752-bib-0028","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study","volume":"363","author":"Mamdani","year":"2004","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0029","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","article-title":"Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"368","author":"Cannon","year":"2006","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0030","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0031","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction","volume":"319","author":"Multicenter Diltiazem Postinfarction Trial Research Group","year":"1988","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0032","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"2026012115035710500_ehf212752-bib-0033","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.94.3.346","article-title":"Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial","volume":"94","author":"Figulla","year":"1996","journal-title":"Circulation"},{"key":"2026012115035710500_ehf212752-bib-0034","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9149(90)90351-Z","article-title":"Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II\u2014DAVIT II)","volume":"66","year":"1990","journal-title":"Am J Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"Cardiac Arrhythmia Suppression Trial (CAST) Investigators","year":"1989","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0036","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"K\u00f8ber","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012115035710500_ehf212752-bib-0037","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0038","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2026012115035710500_ehf212752-bib-0039","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006239","article-title":"Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: a nested case\u2013control study","volume":"96","author":"Girouard","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2026012115035710500_ehf212752-bib-0040","article-title":"Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS ONE"},{"key":"2026012115035710500_ehf212752-bib-0041","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCHEARTFAILURE.112.967356","article-title":"Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure","volume":"5","author":"Allen","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026012115035710500_ehf212752-bib-0042","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2016.05.060","article-title":"Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure","volume":"68","author":"Doshi","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012115035710500_ehf212752-bib-0043","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pds.2146","article-title":"Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients","volume":"20","author":"Li","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12752","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1862\/65902134\/eschf_7_4_1862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/4\/1862\/65902134\/eschf_7_4_1862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:04:50Z","timestamp":1769025890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/4\/1862\/8372997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,17]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,17]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12752","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,17]]},"assertion":[{"value":"2019-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}